An interventional study of Complex Decongestive Therapy and Scapulothoracic Stabilization and Postural Training in Secondary Lymphedema, sponsored by Toros University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Toros University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Lymphedema with a site in Turkey — 12 open to participants now, 16 under way, none of them phase 3. Lymphedema · Turkey.
Among the 65 studies in Lymphedema with a site in Turkey, this one is the 10th largest by planned enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 62nd registered.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
Browse Lymphedema studies →12 of the 65 studies in Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:
Gazi University · Sites in Turkey
Ages 18–80
Toros University · Sites in Turkey
Ages 18–65 · Women only
University Hospital, Basel, Switzerland · Sites in Turkey, United States, Austria and 8 more countries
Ages 18+
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Sites in Turkey
Ages 18–65
Gaziosmanpasa Research and Education Hospital · Sites in Turkey
Ages 18–75
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 52 across 369 interventional studies indexed under Lymphedema.
Median enrollment 40 across the 45 interventional studies, 70 across the 20 observational. Of the 41 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 65 have an industry lead sponsor. The 10 most frequent:
Toros University is the lead sponsor of 21 studies on the registry; 11 are open to participants now.
Toros University has 2 studies filed under Lymphedema — fewer than ten, so there is no comparison to draw.
6 of the studies in Lymphedema with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07919093Halic UniversityComparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema | 2027-01 |
| NCT07043140Inonu UniversityMobile Self-Management Training for Lymphedema Prevention | 2027-01-30 |
| NCT07626645Gazi UniversityExtracorporeal Shock Wave Therapy in Lower Extremity Lymphedema | 2027-02-01 |
| NCT07697495Toros UniversityScapulothoracic Stabilization and Postural Training in Upper Extremity Lymphedema | 2027-03 |
| NCT07697482Toros UniversityRespiratory and Relaxation Training in Lower Extremity Lymphedema | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 65 studies in Lymphedema with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center randomized controlled trial aims to investigate the effects of adding scapulothoracic stabilization and postural training to standard lymphedema care in women with secondary upper extremity lymphedema following breast cancer surgery. Participants will be randomly assigned to receive either standard lymphedema care alone or standard care combined with scapulothoracic stabilization and postural training. Outcomes including scapular muscle strength, posture, upper extremity function, limb volume, and neck awareness will be assessed at baseline, immediately after treatment, and at a 2-month follow-up. The findings are expected to provide evidence regarding the effectiveness of incorporating targeted stabilization and postural exercises into conventional lymphedema rehabilitation.
Secondary upper extremity lymphedema is a common complication following breast cancer treatment and is characterized by chronic swelling, pain, reduced muscle strength, impaired upper extremity function, and postural alterations. These impairments may negatively affect daily activities, body perception, and quality of life. Although Complex Decongestive Therapy (CDT) is considered the gold standard for lymphedema management, conventional treatment primarily focuses on edema reduction and does not specifically address scapular stability, postural alignment, or neuromuscular control.
Altered scapulothoracic biomechanics and postural dysfunction are frequently observed in individuals with breast cancer-related lymphedema. These impairments may contribute to shoulder dysfunction, muscle weakness, compensatory movement patterns, and persistent functional limitations. Scapulothoracic stabilization exercises aim to restore scapular muscle balance and improve dynamic shoulder stability, whereas postural training promotes optimal alignment and body awareness. The combined application of these interventions may enhance functional recovery beyond the effects of standard CDT alone; however, evidence from randomized controlled trials remains limited.
This single-center, prospective, randomized controlled trial aims to evaluate the effectiveness of adding scapulothoracic stabilization and postural training to standard lymphedema care in women with secondary upper extremity lymphedema following breast cancer surgery. Participants will be randomly allocated to either a control group receiving standard lymphedema care or an intervention group receiving standard care plus scapulothoracic stabilization and postural training. Randomization will be performed using a computer-generated allocation sequence, and all outcome assessments will be conducted by a blinded assessor.
Outcome measures will be collected at baseline, immediately after completion of treatment, and at a 2-month follow-up. Primary and secondary outcomes will include scapular muscle strength measured with a handheld dynamometer (MicroFET2), postural alignment assessed using the PostureScreen application, upper extremity function evaluated with the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, limb volume calculated from serial circumference measurements, and neck awareness assessed using the Fremantle Neck Awareness Questionnaire (FreNAQ). The findings of this study are expected to provide evidence regarding the clinical benefits of incorporating targeted scapulothoracic stabilization and postural training into conventional lymphedema rehabilitation and may contribute to the development of more comprehensive rehabilitation protocols for breast cancer survivors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the experimental group will receive standard Complex Decongestive Therapy (CDT), including manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises, together with a structured scapulothoracic stabilization and postural training program. The additional exercise program is designed to improve scapular muscle function, postural alignment, and upper extremity function. Assessments will be performed at baseline, immediately after treatment, and at a 2-month follow-up.
Procedure: Complex Decongestive Therapy · Behavioral: Scapulothoracic Stabilization and Postural Training
Participants assigned to the control group will receive standard Complex Decongestive Therapy (CDT), including manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises according to routine clinical practice. Outcome assessments will be performed at baseline, immediately after treatment, and at a 2-month follow-up.
Procedure: Complex Decongestive Therapy
Standard Complex Decongestive Therapy consisting of manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises. Treatment will be delivered according to established clinical guidelines and routine lymphedema rehabilitation protocols.
A supervised exercise program consisting of scapulothoracic stabilization exercises and postural training designed to improve scapular muscle strength, postural alignment, and upper extremity function. The program will be provided in addition to standard Complex Decongestive Therapy throughout the treatment period.
Change in Upper Extremity Function
Upper extremity function will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH is a validated 30-item patient-reported outcome measure evaluating symptoms and functional limitations of the upper extremity. Scores range from 0 to 100, with higher scores indicating greater disability.
Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment
Change in Head Anterior Translation
Head anterior translation will be assessed using the PostureScreen mobile application.
Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment
Change in Shoulder Height Asymmetry
Shoulder height asymmetry will be assessed using the PostureScreen mobile application.
Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment.
Change in Shoulder Anterior Translation
Shoulder anterior translation will be assessed using the PostureScreen mobile application.
Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment.
Change in Scapular Muscle Strength
Scapular muscle strength (upper, middle, and lower trapezius muscles) will be measured using a handheld dynamometer (MicroFET2) with the isometric make-test method.
Time frame: Baseline, immediately after completion of treatment, and 2 months after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's planned 12 months is below that.
Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Toros University